• Shaoyun Zhao, Zhe Gong, Jing Zhang, Xiaoge Xu, Peidong Liu, Wenjuan Guan, Lijun Jing, Tao Peng, Junfang Teng, and Yanjie Jia.
• Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Clinical Medicine, Zhengzhou University, Zhengzhou, China.
• J Stroke Cerebrovasc Dis. 2015 Aug 1; 24 (8): 1709-14.

BackgroundFew studies have examined the relationship between mircroRNAs and moyamoya disease (MMD). We performed a study of the significance of let-7c expression in the serum of MMD patients.MethodsThe experimental group includes 49 MMD patients, and the control group consists of 30 normal people, 20 cerebral hemorrhage patients, 20 massive cerebral infarction patients, 20 nonmassive cerebral infarction patients, and 20 neurological autoimmune disease patients. Let-7 family levels were determined by polymerase chain reaction. A dual luciferase assay was used to test whether let-7c recognized the 3'UTR of RNF213.ResultsThe expression level of let-7c in MMD patients is higher than that observed in the control groups (P < .001). The luciferase assay results indicated that hsa-let-7c could diminish luciferase activity from a reporter vector containing the 3'-UTR of RNF213 (P < .05). The suppression of luciferase activity is not found in mutRNF213 (P > .05).ConclusionsIncreased expression of let-7c in MMD patients may contribute to MMD pathogenesis by targeting RNF213. Thus, let-7c may be a potential biomarker for the diagnosis of MMD.Copyright © 2015 National Stroke Association. Published by Elsevier Inc. All rights reserved.

26 keywords...

hide…